ObsEva Appoints Elke Bestel as Chief Medical Officer and Jean-Pierre Gotteland as Chief Scientific Officer
(Thomson Reuters ONE) -
ObsEva SA /
ObsEva Appoints Elke Bestel as Chief Medical Officer and Jean-Pierre Gotteland
as Chief Scientific Officer
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Geneva, Switzerland, 22 September 2015 - ObsEva, a Swiss biopharmaceutical
company developing a novel generation of drugs addressing serious conditions
compromising pregnancy from conception to birth, announced today new
appointments to its Management Team.
Elke Bestel joins ObsEva as Chief Medical Officer & Head of Pharmacovigilance
bringing 19 years of experience in pharmaceutical product development.
Prior to joining ObsEva, Elke was the CMO at PregLem, a Swiss based specialty
biopharmaceutical company. She was one of the key players in the successful
development and European registration of Esmya® (treatment of uterine
fibroids). Prior to PregLem, she worked for Galderma, France, where she was
responsible for clinical studies as well as development, registration and life-
cycle activities of dermatological products (Epiduo®, Soolantra®, Adapalene® and
Clindagel®). Before joining Galderma, she worked at the clinical research
organization MDS, France where she was responsible for the conduct of clinical
studies from Phase I to III.
Elke holds a MD degree from the University of Göttingen, Germany, and received
training in gynecology at the Kantonsspital Bruderholz, Switzerland.
Jean-Pierre Gotteland joins ObsEva as Chief Scientific Officer. He has over 20
years' experience in the pharmaceutical industry in all product development
stages particularly in research, preclinical development and early clinical
development.
After an early career at Pierre Fabre Medicament (France), Jean-Pierre joined
Serono in 1998 (subsequently Merck Serono) where he was responsible for various
research and preclinical development programs in the areas of neurology,
autoimmune disorders, endocrinology, metabolism and oncology. In 2007, he was
one of the first employees to join PregLem, a Swiss based specialty
biopharmaceutical company. As VP Non Clinical Development & CMC then Chief
Development Officer, he actively contributed to the successful European
registration of Esmya® (treatment of uterine fibroids), PregLem's lead product
as well as to the progression of development of product portfolio.
Jean-Pierre holds a PhD in Organic Chemistry from the University Claude Bernard
(Lyon, France) and an Engineering Diploma from Ecole Superieure de Chimie
Industrielle (Lyon, France). He was a postdoctoral fellow at the University of
Berkeley (California, USA), and he is the author and co-author of more than 40
publications and 30 patents.
"I am delighted to welcome Elke and Jean-Pierre at ObsEva, as I had the
opportunity to extensively witness their drug development experience and
capacity at PregLem. It is also very timely as ObsEva is actively enlarging its
portfolio of products in development" stated Ernest Loumaye, CEO and Co-Founder
of ObsEva.
- ends -
About ObsEva
ObsEva is a clinical stage biopharmaceutical company focusing on the development
of a novel generation of drugs addressing serious conditions compromising
pregnancy from conception to birth. Our lead programs target the underserved
problems of infertility and preterm labor affecting more and more women
worldwide. The ObsEva team's unique development expertise is supported by top-
tier investors in order to build a leading company in pregnancy pharmaceuticals.
www.ObsEva.com
For more information, please visit www.ObsEva.com
For further information, please contact ObsEva CEO Office:
Delphine Renaud
Tel: +41 22 552 1550
Email: delphine.renaud(at)obseva.ch
Press release (PDF):
http://hugin.info/157613/R/1953402/710833.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: ObsEva SA via GlobeNewswire
[HUG#1953402]
Unternehmensinformation / Kurzprofil:
Datum: 22.09.2015 - 08:30 Uhr
Sprache: Deutsch
News-ID 421645
Anzahl Zeichen: 4966
contact information:
Town:
Plan-les-Ouates
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ObsEva Appoints Elke Bestel as Chief Medical Officer and Jean-Pierre Gotteland as Chief Scientific Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
ObsEva SA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
